Publications by authors named "Ann-Katrin Regensburger"
Article Synopsis
- Belantamab mafodotin is an innovative drug approved for treating multiple myeloma patients who have not responded to other therapies, providing an alternative for those who can't use CAR-T or bispecific antibodies.
- The drug's unique ocular side effects, like corneal microcysts and keratopathy, pose challenges for broader usage, and the study identifies a possible mechanism through which the drug affects the eyes via soluble BCMA (sBCMA) in tear fluid.
- Results show that inhibiting the uptake of sBCMA could prevent keratopathy, suggesting that future treatment strategies might involve using different therapies before administering belantamab or combining it with gamma-secretase inhibitors in ongoing research.
Systemic sclerosis (SSc) is a severe chronic autoimmune disease with high morbidity and mortality. Sera of patients with SSc contain a large variety of autoantibody (aab) reactivities. Among these are functionally active aab that bind to G protein-coupled receptors (GPCR) such as C-X-C motif chemokine receptor 3 (CXCR3) and 4 (CXCR4).
View Article and Find Full Text PDFBackground: The chemokine receptors CXCR3 and CXCR4 are involved in the pathogenesis of fibrosis, a key feature of systemic sclerosis (SSc). It is hypothesized that immunoglobulin (Ig)G antibodies (abs) against these two receptors are present in patients with SSc and are associated with clinical findings.
Methods: Anti-CXCR3 and anti-CXCR4 ab levels were measured in 449 sera from 327 SSc patients and in 234 sera from healthy donors (HD) by enzyme-linked immunosorbent assay (ELISA).